Souhaitez-vous accéder aux communiqués récents ?

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 Halle (Saale) / Munich, Germany, June 8, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...

Louvain-La-Neuve, Belgium, June 08, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy...

Louvain-la-Neuve, Belgique, le 8 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de...

TGS Acquires Apparition Geoservices to Deliver a Step-Change in Seismic Efficiency and Subsurface Imaging

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust...

Regulated Information – Inside information Nyrstar NV provides an update with regards to the Antwerp criminal investigation 8 June 2026 at 07.00 CEST Nyrstar NV (the "Company") was notified on 6...

Gereglementeerde informatie – Voorwetenschap Nyrstar NV geeft een update met betrekking tot het Antwerpse strafonderzoek 8 juni 2026 om 07.00 uur CEST Nyrstar NV (de “Vennootschap”) werd op 6 juni...

Aktsiaselts Infortar on perioodil 1. juuni – 5. juuni 2026 omandanud Nasdaq Tallinna börsil oma aktsiaid järgnevalt:  KuupäevKoondmaht (tk)Kaalutud keskmine päevahind...

Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn StTemplate Manager ock Exchange during the period of 1 June – 5 June 2026 as follows: DateAggregated volume (pcs)Weighted average...

Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche’s oncology pipeline and offers potential...